

# **CADRENAL THERAPEUTICS, INC.**

Reported by  
**MURPHY JOHN RAYMOND**

## **FORM 4**

(Statement of Changes in Beneficial Ownership)

Filed 10/13/26 for the Period Ending 10/09/26

|             |                                                      |
|-------------|------------------------------------------------------|
| Address     | 822 A1A NORTH<br>SUITE 306<br>PONTE VEDRA, FL, 32082 |
| Telephone   | 904-300-0701                                         |
| CIK         | 0001937993                                           |
| Symbol      | CVKD                                                 |
| Fiscal Year | 12/31                                                |

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or  
Section 30(h) of the Investment Company Act of 1940

|                                                                                                                                                                                                                                                                                                                          |                                                                                          |                                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Name and Address of Reporting Person *<br><b>MURPHY JOHN RAYMOND</b><br><br>(Last) (First) (Middle)<br><b>C/O CADRENAL THERAPEUTICS, INC.</b><br><b>822 A1A NORTH, SUITE 306</b><br><br>(Street)<br><b>PONTE VEDRA FLORIDA 32082</b><br><br>(City) (State) (Zip/Postal Code)<br><b>UNITED STATES</b><br><br>(Country) | 2. Issuer Name and Ticker or Trading Symbol<br><b>Cadrenal Therapeutics, Inc. [CVKD]</b> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)<br><br><input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner<br><input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) |
| 3. Date of Earliest Transaction (MM/DD/YYYY)<br><b>10/9/2026</b>                                                                                                                                                                                                                                                         |                                                                                          | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><br><input checked="" type="checkbox"/> Form filed by One Reporting Person<br><input type="checkbox"/> Form filed by More than One Reporting Person                                                   |
| 4. If Amendment, Date Original Filed (MM/DD/YYYY)                                                                                                                                                                                                                                                                        |                                                                                          |                                                                                                                                                                                                                                                                      |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any | 3. Trans. Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |            |       | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|----------------|-----------------------------------|---------------------------|---|-------------------------------------------------------------------|------------|-------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
|                                 |                |                                   | Code                      | V | Amount                                                            | (A) or (D) | Price |                                                                                               |                                                          |                                                       |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |                            | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|------------------------------------------|--------------------------------------------------------|----------------|-----------------------------------|---------------------------|---|----------------------------------------------------------------------------------------|-----------------------------------------|-----------------|-----------------------------------------------------------------------------------|----------------------------|--------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------|
|                                          |                                                        |                |                                   | Code                      | V |                                                                                        | Date Exercisable                        | Expiration Date | Title                                                                             | Amount or Number of Shares |                                            |                                                                                                    |                                                                                  |                                                        |
| Stock Option                             | \$0.91                                                 | 10/9/2026      |                                   | A                         |   | 75,000 (1)                                                                             | 10/9/2026 (1)                           | 10/8/2036       | Common Stock                                                                      | 75,000                     | \$0                                        | 75,000                                                                                             | D                                                                                |                                                        |

Explanation of Responses:

(1) The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026.

Reporting Owners

| Reporting Owner Name / Address                                                                                                         | Relationships |           |         |       |
|----------------------------------------------------------------------------------------------------------------------------------------|---------------|-----------|---------|-------|
|                                                                                                                                        | Director      | 10% Owner | Officer | Other |
| MURPHY JOHN RAYMOND<br>C/O CADRENAL THERAPEUTICS, INC.<br>822 A1A NORTH, SUITE 306<br>PONTE VEDRA<br>FLORIDA<br>32082<br>UNITED STATES | X             |           |         |       |

Signatures

/s/ Quang X. Pham, Attorney-in-fact

10/13/2026

Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

\* Form 4: SEC 1474 (03-26).